Visit booth 100 to learn how Covalon's
products are uniquely designed to help prevent CLABSIs and SSIs
while providing more gentle, compassionate experiences for neonates
and young children.
MISSISSAUGA, ON, Feb. 20,
2023 /CNW/ - Covalon Technologies Ltd. (the "Company"
or "Covalon") (TSXV: COV) (OTCQX: CVALF), an advanced medical
technologies company, today announced its participation for the
first time in the Conference for Neonatology in Las Vegas, Nevada from Wednesday, February 22 to Friday, February 24, 2023 ("NEO"). The NEO
conference brings together global experts, healthcare providers,
academia, and industry, with a focus on improving the level of care
being provided to infants in neonatal intensive care units
("NICUs"). Healthcare providers looking for solutions that help
prevent infection, improve patient outcomes, and reduce stress on
care providers should visit Covalon at booth 100 to learn more
about the unique compassionate care solutions Covalon provides to
top pediatric hospitals throughout the
United States.
NEO was designed for participants to better understand and
utilize the leading approaches to neonatal intensive
care. Amongst renowned experts in neonatal-perinatal care,
Covalon will be presenting its compassion-driven, innovative
solutions designed specifically to help protect infants and
children from infection, while reducing stress and suffering in
both patients and care providers
"Every child deserves an equal opportunity to reach their full
potential," said Ron Hebert, Senior
Vice President, Global Marketing, Covalon. "We now know how
important the first weeks of life are, and it's critical that we
work to help support lifelong favorable outcomes with unique,
patient-centered and compassion-driven medical technology. Major
pediatric hospitals have implemented use of Covalon's infection
prevention solutions and have gone on to observe improving
infection rates." Covalon's compassionate care technology is
already being utilized by 6 of the top 10 children's hospitals, as
ranked by U.S. News & World Report, and is quickly becoming a
standard of care in many prestigious pediatric hospitals across the
U.S.
Covalon's infection prevention solutions include:
- VALGuard® - an FDA listed, transparent,
environmental barrier designed to protect catheter hubs and line
connections from external contaminants and gross contamination,
including body fluids and other secretions. It incorporates a
quick-release pull strip for fast access to infusion hubs and for
easy removal.
- IV Clear® - the world's only dual-antimicrobial
vascular access dressing that offers complete transparency at and
around the insertion site for easy daily assessment. It uses a soft
silicone adhesive to minimize skin injuries and preserve skin
barrier functions and incorporates safe amounts of antimicrobials,
without sacrificing efficacy, to protect against chemical
irritation.
- SurgiClear® - the world's only
dual-antimicrobial clear postoperative dressing that provides full
surgical site visibility, allowing for visual site inspection and
thus eliminating the need for early and multiple dressing
removals.
- CovaClear® IV – utilizes the same trusted
silicone adhesive technology to protect patients from skin injuries
but does not incorporate antimicrobials for use with patients who
either don't require or cannot tolerate antimicrobials.
Conference Details
Date:
Wednesday, February 22, 2023,
8:00am PST to Friday, February 24, 2023, 4:00pm PST
Venue:
Caesars Palace, Las Vegas, NV
Register at:
https://pediatrix.cloud-cme.com/course/courseoverview?P=5&EID=1193
For healthcare providers who are not able to attend the
conference but are interested in learning more about Covalon's
solutions, visit www.covalon.com or follow Covalon on
LinkedIn, Facebook, Instagram or Twitter.
To learn more about Covalon, please
contact:
Brian Pedlar,
CEO, Covalon Technologies Ltd.
Email:
bpedlar@covalon.com
Phone:
905.568.8400 x 233
Toll-Free:
1.877.711.6055
Website:
https://covalon.com/
Twitter:
@covalon
About Covalon
Covalon Technologies Ltd. is a patient-driven medical device
company, built on the relentless pursuit to help the most
vulnerable patients have a better chance at healing. Through a
strong portfolio of patented technologies and solutions for
advanced wound care, infection prevention, and medical device
coatings, we offer innovative, gentler, and more compassionate
options for patients to heal with less infections, less pain, and
better outcomes. Our solutions are designed for patients and made
for care providers. Covalon leverages its patented medical
technology platforms and expertise in two ways: (i) by developing
products that are sold under Covalon's name; and (ii) by developing
and commercializing medical products for other medical companies
under development and license contracts. The Company is listed on
the TSX Venture Exchange, having the symbol COV and trades on the
OTCQX Market under the symbol CVALF. To learn more about Covalon,
visit our website at www.covalon.com
Neither the TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
This news release may contain forward-looking statements
which reflect the Company's current expectations regarding future
events. The forward-looking statements are often, but not always,
identified by the use of words such as "seek", "anticipate", "plan,
"estimate", "expect", "intend", or variations of such words and
phrases or state that certain actions, events, or results "may",
"could", "would", "might", "will" or "will be taken", "occur", or
"be achieved". In addition, any statements that refer to
expectations, projections or other characterizations of future
events or circumstances contain forward-looking information.
Statements containing forward-looking information are not
historical facts, but instead represent management's expectations,
estimates, and projections regarding future events. Forward-looking
statements involve risks and uncertainties, including, but not
limited to, the factors described in greater detail in the "Risks
and Uncertainties" section of our management's discussion and
analysis of financial condition and results of operations for the
year ended September 30, 2022, which
is available on the Company's profile at
www.sedar.com, any of which could cause results,
performance, or achievements to differ materially from the results
discussed or implied in the forward-looking statements. Investors
should not place undue reliance on any forward-looking statements.
The forward-looking statements contained in this news release are
made as of the date of this news release, and the Company assumes
no obligation to update or alter any forward-looking statements,
whether as a result of new information, further events, or
otherwise, except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/infection-prevention-solutions-provider-covalon-to-participate-for-the-first-time-in-neo---the-conference-for-neonatology-in-las-vegas-nv-on-february-22-24-2023-301750346.html
SOURCE Covalon Technologies Ltd.